NSRX Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $18.00. The high target offers 877.78% upside. The low target suggests 700.0% downside. The mean target is $19.67. This offers 774.22% upside.

NSRX has shown weak momentum, losing -10.68% over the past week and -4.26% over the past quarter, though year-to-date performance is down -28.74%. Short-term trend indicators are bullishly aligned (SMA20 -7.9%, SMA50 -21.08%, SMA200 -29.02%). The stock’s 14-day RSI is 41.5 (neutral), while the ATR of 0.69 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.95% below its high and over 4.08% above its low. Average 10-day trading volume of 27.22 thousand shares is below the 3-month average of 175.02 thousand, indicating normal recent market interest.

Nasus Pharma Ltd. has 9.06 million shares outstanding. The public float is 2.49 million shares, elevated short interest at 0.31% of float. This equals 12.25 thousand shares. The short ratio is 0.09 days. Institutional investors hold 0.0% of the float. Insiders own 59.33%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Nasus Pharma Ltd. (AMEX:NSRX) closed at $2.25 USD, gaining $0.04 (1.81%) from the previous close of $2.21. The stock is currently mid-range between its 52-week high and low $1.98 and $9.99. With a market capitalization of about $19.38 million, Nasus Pharma Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~5.02). Key stats such as the average daily volume over the past year has been around 169.83 thousand shares, volume is running light vs its 52-week average. Headquartered in Tel Aviv, None, Nasus Pharma Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dan Teleman, the company employs approximately 2 people and listed since August 13, 2025. Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Our AI price prediction model suggests that Nasus Pharma Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -44.0%, with price expected at $1.26 by April 28, 2026, within a range of $0.69 to $1.86 3-Month Outlook: Projected rise of 115.11%, reaching $4.84 by July 13, 2026, with a range of $4.70 to $5.00. 1-Year Outlook: Projected loss of -94.22%, with price at $0.13 by April 14, 2027, within a range of $0.02 to $0.23.

Nasus Pharma Ltd. (AMEX:NSRX) shares are down -28.74% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Nasus Pharma Ltd. trading at a premium to the broader market with a P/E of -13.36. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $19.67, suggesting 774.22% upside. Our AI forecast model points to short-term weakness (-44.0% over two weeks), a medium-term rise (115.11% over three months), and a longer-term loss (-94.22% over one year), with expected trading ranges indicating moderate volatility.

Nasus Pharma Ltd. trades at a P/E ratio of -13.36, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at 0.0, also below market averages.